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Abstract
Background and Aim: Chronic graft‐versus‐host disease (cGVHD) is a major
cause of nonrelapse morbidity and mortality following hematopoietic stem cell
transplantation (HSCT). α‐Galactosylceramide (α‐GC) is a synthetic glycolipid that
is recognized by the invariant T‐cell receptor of invariant natural killer T (iNKT)
cells in a CD1d‐restricted manner. Stimulation of iNKT cells by α‐GC leads to the
production of not only immune‐stimulatory cytokines but also immune‐regulatory
cytokines followed by regulatory T‐cell (Treg) expansion in vivo.
Methods: We investigated the effect of iNKT stimulation by liposomal α‐GC
just after transplant on the subsequent immune reconstitution and the de-
velopment of sclerodermatous cGVHD.
Results: Our study showed that multiple administrations of liposomal α‐GC
modulated both host‐ and donor‐derived iNKT cell homeostasis and induced an
early expansion of donor Tregs. We also demonstrated that the immune mod-
ulation of the acute phase was followed by the decreased levels of CXCL13 in
plasma and follicular helper T cells in lymph nodes, which inhibited germinal
center formation, resulting in the efficient prevention of sclerodermatous cGVHD.
Conclusions: These data demonstrated an important coordination of T‐ and
B‐cell immunity in the pathogenesis of cGVHD and may provide a novel
clinical strategy for the induction of immune tolerance after allogeneic HSCT.
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1 | INTRODUCTION
Chronic graft‐versus‐host disease (cGVHD) is a major
cause of nonrelapse morbidity and mortality following
hematopoietic stem cell transplantation (HSCT),1 while
effective prophylaxis and therapies for cGVHD are still
lacking.2 CD4+CD25+Foxp3+ regulatory T cells (Tregs)
play an indispensable role in the maintenance of toler-
ance after allogeneic HSCT.3 It has been reported that
adoptive transfer of donor‐type Tregs could prevent the
onset of acute GVHD in murine bone marrow trans-
plantation (BMT) models and human clinical trials,4 and
the administration of low‐dose interleukin‐2 (IL‐2) to
patients with active cGVHD increased the levels of per-
ipheral Tregs and ameliorated the clinical symptoms.5,6
These results suggest that in vivo modulation of Tregs is
a promising strategy to control aggressive GVHD after
allogeneic HSCT.
α‐Galactosylceramide (α‐GC) is a synthetic glycolipid,
which is recognized by the invariant T‐cell receptor of
invariant natural killer T (iNKT) cells in a CD1d‐restricted
manner.7 Stimulation of iNKT cells by α‐GC leads to the
production of not only immune‐stimulatory cytokines
but also immune regulatory cytokines such as IL‐4 and
IL‐10, followed by Treg expansion in vivo.8 Previous
studies in mice have shown that the administration of
an aqueous α‐GC stimulated host‐type iNKT cells and
ameliorated acute GVHD by expanding donor Tregs via
production of IL‐4.9,10 Subsequently, a liposomal α‐GC
(lipo α‐GC) was developed and reported to be tolero-
genic and safe in vivo11; furthermore, its acute GVHD‐
preventing effect was proven in a murine model.12
Based on these findings, a phase 2 clinical trial was
performed, which demonstrated that the administration
of lipo α‐GC immediately after HSCT contributed to the
prevention of acute GVHD, and the effects were
dependent on Treg expansion.13 Moreover, the admin-
istration of lipo α‐GC prevented and ameliorated
cGVHD in a lung cGVHD mouse model.14
The significance of B‐cell immunity in cGVHD has
been increasingly recognized. Thus, it has been reported
that an abnormality in B‐cell homeostasis was related to
the development of cGVHD in humans.15 In addition, it
has been observed that T follicular helper (Tfh) cells
played a role in cGVHD patients. A recent analysis of
clinical samples from post‐HSCT patients demonstrated
that Tfh cells were significantly reduced in the peripheral
blood and the plasma concentration of CXCL13, a
CXCR5 ligand, was elevated in patients with active
cGVHD, suggesting that migration of Tfh cells from
peripheral blood to lymphoid organs is one of the im-
portant processes in cGVHD.16 Recent studies in mice
have shown that the excessive reaction between Tfh cells
and germinal center B (GCB) cells resulted in the de-
position of the IgG alloantibody, leading to tissue damage
in cGVHD target organs.17,18 Based on these findings,
inhibitors of Bruton's tyrosine kinase and spleen tyrosine
kinase, which are downstream signaling molecules of the
B‐cell receptor, have been studied as treatments for
steroid‐resistant cGVHD.19–21
It is known that patients with active cGVHD have a
lower frequency of Tregs than do patients without
cGVHD.22 Recently, an immunological crosstalk between
Tregs and B cells has been reported in various fields.
Tregs and T follicular regulatory cells were shown to
suppress Tfh‐cell activation and germinal center forma-
tion, which could control humoral immunity in mice
after vaccination.23 Adoptive transfer of donor Tregs al-
lowed their infiltration into the germinal center and
modulated B‐cell differentiation, resulting in ameliora-
tion of murine cGVHD in a CXCR5‐dependent manner.24
Here, we hypothesized that donor Treg expansion by
lipo α‐GC modulates B‐cell immunity after HSCT and
prevent the onset of cGVHD. To explore this hypothesis, we
investigated the clinical effects and immune mechanisms of
lipo α‐GC in a murine sclerodermatous cGVHD model.
2 | MATERIALS AND METHODS
2.1 | Mice
Female BALB/c (H‐2d) and B10.D2 (H‐2d) mice were
purchased from Japan SLC. The mice were 10 weeks of
age at the time of BMT. All mice were housed under
specific pathogen‐free conditions and treated in strict
compliance. All animal experiments were performed
according to the regulations of the Animal Care and Use
Committee, Okayama University Advanced Science Re-
search Center.
2.2 | Mouse models and assessment of
skin cGVHD
To generate an allogeneic mouse model, BALB/c mice
received 6 Gy of total‐body irradiation (TBI), which
consisted of two doses administered at a 6‐h interval to
minimize gastrointestinal toxicity. The irradiated host
mice were intravenously injected with 10 × 106 bulk
spleen cells and 8 × 106 bone marrow (BM) cells from
B10.D2 mice. In a syngeneic mouse model, BALB/c mice
received the same dose of TBI and were intravenously
injected with the same doses of spleen and BM cells from
BALB/c mice. Mice were monitored twice a week and
scored for skin manifestations of GVHD. The following
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scoring system was used: healthy appearance, 0; skin
lesions with an alopecia area < 1 cm2, 1; skin lesions with
an alopecia area of 1–2 cm2, 2; and skin lesions with an
alopecia area > 2 cm2, 3. In addition, animals were as-
signed 0.3 points each for skin disease (lesions or scaling)
on the ears, tail, and paws. The minimum score was 0,
and the maximum score was 3.9.25
2.3 | Administration of lipo α‐GC
RGI‐2001 (lipo α‐GC) was provided by REGiMMUNE.
We administered either lipo α‐GC (at a dose of 1 μg/kg)
or a saline vehicle by tail‐vein injection on Days 0, 3, and
5 after BMT.
2.4 | Administration of anti‐IL‐4
antibody
Anti‐IL4 antibody (Ultra‐LEAFTM Purified antimouse
IL‐4, Biolegend) was administered intraperitoneally on
Days 0, 3, and 5 after BMT. Administration doses of the
antibody were 2 mg on Day 0, and 1mg on Days 3 and 5,
respectively.
2.5 | Depletion of CD25+ cells from the
spleen cell population
Depletion of CD25+ cells was performed using a
PE‐conjugated anti‐CD25 monoclonal antibody and mi-
crobeads (Miltenyi Biotec). Whole‐spleen cells harvested
from donor mice were labeled with PE‐CD25 and anti‐PE
microbeads, and CD25− cells were negatively purified by
magnetic separation using an AutoMACS system (Mil-
tenyi Biotec). The purity of the CD25−CD4+ T‐cell frac-
tions was above 95%.
2.6 | Flow cytometry
Single‐cell suspensions were first incubated with the
following directly conjugated monoclonal antibodies
(obtained from eBioscience, unless stated otherwise)
for 20min at 4°C: eFluor450‐conjugated anti‐B220
(RA3‐6B2), anti‐CD4 (GK1.5), and anti‐TCR‐β (H57‐597);
FITC‐conjugated anti‐GL7 (GL7; BioLegend) and
anti‐Ly9.1 (30C7; BD Bioscience); phycoerythrin
(PE)‐conjugated anti‐PD‐1 (RMP1‐30) and anti‐α‐
GC‐loaded CD1d tetramer (Proimmune); PE‐Cy7‐
conjugated anti‐CD25 (PC61.5); allophycocyanin
(APC)‐conjugated anti‐Fas (SA367H8, BioLegend);
and APC‐eFluor780‐conjugated anti‐CXCR5 (L138D7,
BioLegend) and anti‐CD19 (eBio1D3). For intracellular
staining, cells were processed using a Foxp3 staining
buffer set (eBioscience) and then incubated with
APC‐conjugated anti‐Foxp3 (FJK‐16S) for 30min at 4°C.
Samples were analyzed using a MAQSQuant flow
cytometer (Miltenyi Biotec), and data were analyzed using
the FlowJo software version 10 (TreeStar). flow cytometry
gating strategy for specific lymphocyte subsets is shown in
Figures S1 and S2.
2.7 | Enzyme‐linked immunosorbent
assay
Mouse plasma was collected on Day 56 following HSCT,
and plasma samples were assayed for CXCL13 via
sandwich enzyme‐linked immunosorbent assay using the
Quantikine mouse CXCL13/BLC/BCA‐1 immunoassay
(R&D Systems). Samples were diluted fivefold with the
calibrator diluent and tested along with standards and
calibrator controls, following the manufacturer's
instructions.
2.8 | Tissue histopathology
A shaved skin from the interscapular region (~2 cm2) of
recipients was fixed in 10% formalin, embedded in par-
affin, sectioned, mounted on slides, and stained with
hematoxylin and eosin. Slides were scored by a pathol-
ogist (T. T.) on the basis of dermal fibrosis, fat loss, in-
flammation, epidermal interface changes, and follicular
dropout (0–2 for each category, with the maximum score
of 10).26
2.9 | Statistical analysis
Group comparisons of skin cGVHD scores and skin pa-
thological scores were performed using the
Mann–Whitney U‐test or Kruskal–Wallis test. Cell po-
pulations and cytokine levels were analyzed using an
unpaired two‐tailed Student's t test or one‐way analysis
of variance with Tukey's post hoc test using Prism 7
(GraphPad Software). Spearman's rank correlation ana-
lysis was used to examine the correlation between the
percentage of Tfh cells and the CXCL13 level, skin
cGVHD score, and skin pathological score, respectively,
and the coefficients were calculated using EZR (Saitama
Medical Center, Jichi Medical University, Saitama,
Japan), a graphical user interface for R (R Foundation for
Statistical Computing, Vienna, Austria).27
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3 | RESULTS
3.1 | Administration of lipo α‐GC
improved the skin cGVHD score and
body weight
To investigate whether the administration of lipo α‐GC
prevents sclerodermatous cGVHD, allogeneic and syn-
geneic BMT mice were treated with lipo α‐GC or the
vehicle and monitored for the cGVHD clinical score and
body weight (Figure 1A). The allogeneic host mice trea-
ted with lipo α‐GC (allo lipo α‐GC group) showed sig-
nificantly lower skin cGVHD scores than did the vehicle‐
treated control allogeneic host mice (allo vehicle group).
The body weight tended to be higher in the allo lipo
α‐GC group than in the allo vehicle group, although
there was no significant difference (Figure 1B). The ap-
pearance of the mouse skin on Day 56 was consistent
with the clinical score (Figure 1C). The pathological
score of skin cGVHD in the lipo α‐GC‐treated allogeneic
BMT mice was significantly lower than that in the
vehicle‐treated allogeneic mice (Figure 2A,B). The results
collectively suggested that lipo α‐GC treatment could
protect from the development of sclerodermatous
cGVHD in the allogeneic BMT mouse model.
3.2 | Donor iNKT cells increased, host
iNKT cells decreased, and donor tregs
expanded in an early phase after BMT
To clarify the mechanism of the preventive effect of lipo
α‐GC against cGVHD in an early phase after BMT, we
examined the dynamics of iNKT cells and Tregs by flow
cytometric analysis of spleen cells on Day 7 (Figure 3).
The analysis revealed that the number of donor iNKT
cells in the lipo α‐GC‐treated mice was significantly
higher on Day 7 than that in the vehicle‐treated mice,
while that of host iNKT cells was inversely suppressed on
Day 7 in the spleen (Figure 3A). We confirmed the ki-
netics of iNKT cells in lymph nodes was similar to that in
the spleen (Figure S8). The proportion of donor but not
host Tregs in the lipo α‐GC‐treated mice was significantly
higher on Day 7 than that in the vehicle‐treated mice
(Figure 3B). Tregs in the syngeneic cohorts, where the
inflammation is relatively mild, are basically higher than
Tregs in the allogeneic cohorts (Figure 3C). Addition of
lipo α‐GC increased Treg in allogeneic cohorts, but the
effect was not observed in syngeneic cohorts. These data
suggested that multiple lipo α‐GC administrations mod-
ulate the homeostasis of both host‐ and donor‐derived
iNKT cells, leading to preferential expansion of donor
Tregs after allogeneic transplantation.
3.3 | Preventive effect of lipo α‐GC
against cGVHD was canceled by anti‐IL‐4
antibody
To consider whether the preventive effect of lipo α‐GC
against cGVHD is in an IL‐4 dependent manner, we
performed the additional injection of anti‐IL‐4 antibody
to sclerodermatous cGVHD mouse model treated by lipo
α‐GC (Figure S7). The additional injection of anti‐IL‐4
antibody to lipo α‐GC treated mice on Days 0, 3, and 5
resulted in the development of severe sclerodermatous
GVHD. The data suggest that the tolerogenic activity of
iNKT cells given by lipo α‐GC administration was at least
partially dependent on the production of IL‐4.
3.4 | Depletion of CD25‐positive cells
canceled the expansion of donor Tregs on
Day 7 and the preventive effect of lipo
α‐GC against cGVHD
To clarify the role of donor Tregs in the preventive
effect of lipo α‐GC against cGVHD, we depleted
CD25‐positive cells from the population of donor
spleen cells. As shown in Figure 4A,B the proportion of
donor Tregs in the mice that received CD25‐depleted
spleen cells was significantly lower than that in the
mice that received whole spleen cells, regardless of the
lipo α‐GC treatment. In parallel, the protection against
sclerodermatous cGVHD by lipo α‐GC treatment was
canceled by the transfer of CD25‐depleted spleen cells
(Figure 4C). The results indicated that CD25‐positive
cells in the population of donor spleen cells were in-
dispensable for the protection against sclerodermatous
cGVHD by lipo α‐GC treatment.
3.5 | Follicular helper T cells and GCB
cells decreased in a late phase after BMT
To clarify the mechanism of the preventive effect of lipo
α‐GC against cGVHD in a late phase after BMT, we
analyzed the proportions of Tfh and GCB cells in me-
senteric lymph nodes (MLNs) by flow cytometry on Days
28 and 56 (Figure 5A,B). The results showed that Tfh in
the syngeneic cohorts were in the lower levels than Tfh
in the allogeneic cohorts. Of note, the lipo α‐GC treat-
ment significantly decreased Tfh in allogeneic cohorts on
Days 28 and 56. As well, the lipo α‐GC treatment sig-
nificantly reduced GCB cells on Day 56. These results
suggested that the tolerogenic effect of lipo α‐GC in the
late phase after BMT was associated with the reduction
of both Tfh and GCB cells in MLNs.
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3.6 | Plasma CXCL13 tended to decrease
in the allo lipo α‐GC group and was
correlated with tfh cells in MLNs
Next, we evaluated whether the migration of Tfh cells
into MLNs after BMT could be inhibited by lipo α‐GC
treatment, by measuring the plasma level of CXCL13, a
ligand for CXCR5, which is one of representative mar-
kers of Tfh cells. The plasma concentration of CXCL13 in
the lipo α‐GC‐treated allogeneic mice tended to be lower
than that in the vehicle‐treated allogeneic mice on Day
56 (Figure 6A). Notably, the concentration of CXCL13 in
FIGURE 1 Lipo α‐GC prevents cGVHD in a sclerodermatous cGVHD mouse model. (A) Experimental scheme. BALB/c recipient mice
received 6 Gy of TBI; then, 8 × 106 BM cells and 10 × 106 spleen cells were administered from B10.D2 donor mice. Lipo α‐GC was
administered at a dose of 1 μg/kg via tail vein injection on Days 0, 3, and 5 after BMT. (B) Time courses of skin cGVHD score and percent
body weight changes from baseline after BMT in syngeneic/vehicle (n= 3), syngeneic/lipo α‐GC (n= 3), allogeneic/vehicle (n= 8), and
allogeneic/lipo α‐GC (n= 8) groups. Representative data from one of three independently performed experiments are expressed as the
means ± SEM. p‐values were determined by the Kruskal–Wallis test; *p< .05. (C) Representative photographs of mice from syngeneic/
vehicle (n= 3), syngeneic/lipo α‐GC (n= 3), allogeneic/vehicle (n= 8), and allogeneic/lipo α‐GC (n= 8) groups on Day 56 after BMT from
one of three independently performed experiments. BMT, bone marrow transplantation; BM, bone marrow; cGVHD, chronic graft‐versus‐
host disease; α‐GC, α‐Galactosylceramide
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the plasma was correlated with the proportion of Tfh
cells in the population of CD4+ T cells in MLNs
(Figure 6B). Furthermore, the proportion of Tfh cells in
MLNs on Day 56 was correlated with the skin cGVHD
score and skin pathological score (Figure 6C,D). Taken
together, these results suggested that the prevention of
cGVHD symptoms by lipo α‐GC might be caused by the
reduction of the CXCL13 in the periphery, which may
inhibit the migration of Tfh cells into MLNs.
4 | DISCUSSION
In this study, we demonstrated that multiple lipo α‐GC
administrations were effective for the prevention of dis-
ease symptoms, such as the collapse of the skin and
subcutaneous tissue, in a mouse model of scler-
odermatous cGVHD. We also found that the number of
host iNKT cells in lipo α‐GC‐treated mice was less than
that in control mice on Day 7, while the number of donor
iNKT cells in lipo α‐GC‐treated mice was significantly
higher than that in control mice on Day 7. Our previous
studies using BMT mouse models suggested that host
iNKT cells were indispensable for the induction of
immune tolerance after a single injection of lipo
α‐GC.12,28,29 Other studies using murine acute BMT
models also showed that host‐derived iNKT cells played a
critical role in aqueous α‐GC‐induced immune tolerance,
mediated by the production of IL‐4 and IL‐10.9,10 Our
study showed the preventive effect of sclerodermatous
GVHD by lipo α‐GC was canceled by anti‐IL‐4 antibody,
suggesting that the tolerogenic activity of iNKT cells is in
an IL‐4‐dependent manner. Consistent with our results, a
previous study reported that the direct administration of
IL‐4 resulted in the reduction of Tfh.30 This may suggest
a potential role of type‐2 cytokine in the prevention of
cGVHD.
One might argue that the host iNKT cells in our
model were not involved in the preventive effect because
the number of cells decreased in the spleen. However, we
consider that the disappearance of host iNKT cells from
the periphery was caused by their rapid migration, which
was activated by multiple lipo α‐GC administrations to
the GVHD target organ. In fact, we tried to check iNKT
cells in the skin as the cGVHD target organ. To detect
iNKT cells in the skin, we dissolved the skin with Multi
Tissue Dissolution Kit 1 (Miltenyi Biotic) and stained
cells with CD45, CD19, TCR‐β, and CD1d tetramer.
Unfortunately, however, it was very difficult to identify
iNKT cells from the skin of recipients by flow cytometry
(data not shown). This suggests that there are very few
NKT cells in the skin on Day 7 in recipient mice that
have undergone TBI. Accurate evaluation of this small
subset of cells on GVHD target organs immediately after
transplantation was considered to require the develop-
ment of new methods. The evaluation of skin‐resident
iNKT cells will be needed to further develop NKT‐based
therapy in the future.
Simultaneously, the results also suggest that multiple
lipo α‐GC administrations, rather than a single
FIGURE 2 Lipo α‐GC reduces pathological scores in a sclerodermatous cGVHD mouse model. (A) Representative photomicrographs of
hematoxylin‐ and eosin‐stained skin sections from syngeneic/vehicle, syngeneic/lipo α‐GC, allogeneic/vehicle, and allogeneic/lipo α‐GC
mice on Day 56 after BMT. Scale bar = 100 μm. ×20. (B) Pathological scores of skin cGVHD in syngeneic/vehicle (n= 2, one experiment),
syngeneic/lipo α‐GC (n= 2, one experiment), allogeneic/vehicle (n= 8, data combined from two independently performed experiments with
four mice per experiments), and allogeneic/lipo α‐GC (n= 8, data combined from two independently performed experiments with four mice
per experiments) groups on Day 56. Data are expressed as the means ± SEM. p‐values were determined by the Mann–Whitney U‐test
(allogeneic/vehicle vs. allogeneic/lipo α‐GC); *p< .05. BMT, bone marrow transplantation; cGVHD, chronic graft‐versus‐host disease;
α‐GC, α‐Galactosylceramide
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FIGURE 3 (See caption on next page)
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administration, may accelerate the early emergence of
donor iNKT cells, followed by remarkable preventive
effects. Indeed, recent adoptive transfer studies have re-
ported that the administration of purified donor‐type
iNKT cells, or even third‐party iNKT cells, potently
suppressed GVHD.31,32 Furthermore, similar results were
observed in a systemic lupus erythematosus model, in
addition to GVHD models.33,34 In this study, we found
that the proportion of donor Tregs among CD4+ T cells
was much higher than that of host Tregs, and donor
Tregs were indispensable for the prevention of cGVHD
symptoms. Although this preferential expansion of donor
Tregs after the treatment is beneficial for the prevention
of GVHD, the mechanism still remains unclear. How-
ever, we hypothesize that multiple lipo α‐GC adminis-
trations modulate the homeostasis of both host‐ and
donor‐derived iNKT cells, leading to preferential expan-
sion of donor Tregs.
Various studies investigated the mechanisms of how
the activation of NKT cells result in Treg recruitment and
function and suggested the importance of IL‐4 and IL‐10
in the process.9,10,35 A recent study demonstrated that
activated NKT cells produce IL‐2 which directly acts on
Treg homeostasis.26 Further study will warrant the me-
chanism more precisely and develop NKT‐based therapy
for immune tolerance.
Recent studies have suggested the importance of
B‐cell immunity in the development of cGVHD. Analysis
of clinical samples from patients with cGVHD demon-
strated that the number of Tfh cells was significantly
reduced in the peripheral blood and the plasma con-
centration of CXCL13, a CXCR5 ligand, increased in
patients with active cGVHD, suggesting that the migra-
tion of Tfh cells from peripheral blood to lymphoid or-
gans is one of the important processes in the
development of cGVHD.16 Studies in mice have shown
that the germinal center reaction between Tfh and GCB
cells plays a critical role in cGVHD pathogenesis, and
inhibition of this reaction significantly reduces
cGHVD.17,18 In our study, Tfh and GCB cells significantly
decreased in MLNs of recipients treated with lipo α‐GC,
in line with clinical amelioration of sclerodermatous
cGVHD. In addition, the concentration of CXCL13 in
peripheral blood of lipo α‐GC‐treated allogeneic re-
cipients was substantially lower than that in vehicle‐
treated allogeneic recipients and was correlated with the
proportion of Tfh cells among CD4+ T cell. Furthermore,
the proportion of Tfh cells was significantly correlated
with the skin cGVHD score and skin pathological score.
Based on these results, it was suggested that the pre-
ventive effects of lipo α‐GC against cGVHD might be
related to the inhibition of Tfh and GCB cells. It appears
that the decreased level of CXCL13 after lipo α‐GC
treatment is also an important factor in this process of
cGVHD prevention, needed to avoid the migration of Tfh
cells to lymphoid organs.
It is known that patients with active cGVHD have a
lower frequency of Tregs than do those without
cGVHD.22 Recent studies have revealed an im-
munological crosstalk between Tregs and B cells, which
is important for the germinal center formation in lymph
nodes and B‐cell lymphopoiesis in the BM. Tregs and T
follicular regulatory cells suppress Tfh‐cell activation and
the germinal center formation, which can control hu-
moral immunity in mice after vaccination.23 Adoptively
transferred donor‐derived Tregs infiltrated into the
germinal center and modulated B‐cell differentiation,
resulting in amelioration of cGVHD in a CXCR5‐
dependent manner in mice.24 In murine BMT models,
B‐cell lymphopoiesis is impaired in host Treg‐depleted
mice but is rescued by adoptive transfer of affected he-
matopoietic stem cells or BM cells into Treg‐competent
recipients.36 On the other hand, infusion of splenic T
cells, in which donor Tregs were expanded by an anti‐
DR3 antibody, improved B‐cell lymphopoiesis in a mouse
cGVHD model.37 These studies suggest that both host
and donor Tregs are essential for B‐cell lymphopoiesis in
HSCT. Compared with those of previous studies that
used an adoptive Treg transfer system, our results suggest
that in vivo expansion of donor Tregs by lipo α‐GC may
regulate the germinal center reaction and restore B‐cell
homeostasis in a cGVHD model. In fact, the preventive
effect of lipo α‐GC against cGVHD was significantly
canceled by the depletion of CD25‐positive cells from the
FIGURE 3 Lipo α‐GC increases donor iNKT cells, decreases host iNKT cells, and expands donor Tregs in an early phase after BMT.
Tregs were defined as CD4+FoxP3+CD25+ cells and iNKT cells were defined as CD19−TCR‐β+CD1d tetramer+ cells. Chimerism was
evaluated in the host (Ly9.1+) or donor (Ly9.1−). (A) The number of donor iNKT cells and host iNKT cells in spleen cells after BMT in
vehicle (n= 5, one experiment) and lipo α‐GC (n= 5, one experiment) mice on Day 7. Data are expressed as means ± SEM. p‐values were
determined using an unpaired, two‐tailed Student's t test. *p< .05. (B) Percentages of donor Tregs, and host Tregs among CD4+ T cells in
spleen cells in vehicle (n= 5, one experiment) and lipo α‐GC (n= 5, one experiment) mice on Day 7. Data are expressed as means ± SEM.
p‐values were determined using an unpaired, two‐tailed Student's t test. *p< .05. (C) Percentages of total Tregs among CD4+ T cells in
spleen cells in syngeneic/vehicle (n= 3, one experiment), syngeneic/lipo α‐GC (n= 3, one experiment), allogeneic/vehicle (n= 5, one
experiment) and allogeneic/lipo α‐GC (n= 5, one experiment) mice on Day 7. Data are expressed as means ± SEM. P‐values were
determined using an unpaired, two‐tailed Student's t test. *p< .05. BMT, bone marrow transplantation; iNKT, invariant natural killer T;
α‐GC, α‐Galactosylceramide
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FIGURE 4 CD25 depletion inhibits donor Treg expansion and exacerbates cGVHD scores with lipo α‐GC treatment. (A) Representative
flow cytometry images of donor Tregs (CD4+Ly9.1−FoxP3+CD25+) in whole spleen/vehicle, whole spleen/lipo α‐GC, and CD25‐depleted
spleen/lipo α‐GC mice on Day 7. (B) Tregs and donor Tregs in whole spleen/vehicle (n= 5, one experiment), whole spleen/lipo α‐GC (n= 5,
one experiment), and CD25‐depleted spleen/lipo α‐GC (n= 5, one experiment) groups. Data are expressed as means ± SEM. P‐values were
determined by one‐way analysis of variance with Tukey's post hoc test. ***p< .001; ****p< .0001. (C) Skin cGVHD scores in syngeneic
(n= 3, one experiment), whole allogeneic spleen/vehicle (n= 11, data combined from two independently performed experiments with five
to six mice per experiments), whole allogeneic spleen/lipo α‐GC (n= 11, data combined from two independently performed experiments
with five to six mice per experiments), and allogeneic CD25‐depleted spleen/lipo α‐GC (n= 11, data combined from two independently
performed experiments with five to six mice per experiments) groups. Data are expressed as means ± SEM. p‐values were determined by the
Kruskal–Wallis test. *p< .05. cGVHD,chronic graft‐versus‐host disease; α‐GC, α‐Galactosylceramide
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population of donor spleen cells. We propose that the
expansion of Tregs in a donor inoculum in a very acute
phase may play a critical role in the regulation of pa-
thogenic B‐cell immunity, contributing to the develop-
ment of cGVHD.
Also, previous studies already showed that IL‐10 has
a role in NKT‐mediated tolerance.38 In addition, a recent
study has shown that IL‐10 produced by B cells is im-
portant to suppress GVHD.39 We have previously re-
ported that lipo α‐GC is preferentially taken up by B cells
and further promotes IL‐10 production from B cells.11
These results suggest that B‐cell/IL‐10‐axis has a critical
role in the suppression of GVHD by lipo α‐GC. Further
experiments using an IL‐10 blocking system may eluci-
date the effect and the mechanism of lipo α‐GC on
cGVHD.
The relative proportion of iNKT to CD4+ T cells, Treg
cells, Tfh cells, and GCB cells and Treg to CD4+ T cells, Tfh
cells, GCB cells, and iNKT cells in the spleen on Days 7, 28,
and 56 is shown in Figures S3 and S4. The relative pro-
portion of iNKT to Treg in the spleen on Day 7 decreased in
the lipo α‐GC group significantly. We assumed it might
FIGURE 5 Lipo α‐GC inhibits Tfh and GCB cells in a late phase after BMT. Tfh cells were defined as CD4+CXCR5+PD‐1+ cells and
GCB cells were defined as B220+GL7 +Fas+ cells. (A) Proportions of Tfh cells in MLNs of syngeneic/vehicle (n= 3), syngeneic/lipo α‐GC
(n= 3), allogeneic/vehicle (n= 8) and allogeneic/lipo α‐GC (n= 8) groups on Days 28 and 56. Data were combined from two independently
performed experiments with four mice per experiments and are expressed as the means ± SEM. P‐values were determined using an
unpaired, two‐tailed Student's t test. *p< .05. (B) Proportions of GCB cells in MLNs of vehicle (n= 8), and lipo α‐GC (n= 8) groups on Days
28 and 56. Data were combined from two independently performed experiments with four mice per experiments and are expressed as the
means ± SEM. P‐values were determined using an unpaired, two‐tailed Student's t test. *p< .05. GCB, germinal center B
cell; MLN, mesenteric lymph nodes; Tfh, follicular helper T cell; α‐GC, α‐Galactosylceramide
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reflect increasing Treg and decreased host iNKT in the lipo
α‐GC group. The relative proportion of iNKT to Tfh in the
spleen on Day 28 decreased in the vehicle group sig-
nificantly. We assumed it might reflect the aggressive in-
crease of Tfh in the vehicle group which was consistent with
the development of skin cGVHD. The relative proportion of
Treg to Tfh in the spleen on Days 28 and 56 increased in the
lipo α‐GC group significantly. We assumed it might reflect
the increased Treg and the decreased Tfh in the lipo α‐GC
group which was consistent with our hypothesis that in-
creased Treg could suppress Tfh and skin cGVHD.
The relative proportion of CD4+ T cells, Treg cells,
Tfh cells, and GCB cells to total lymphocyte on Days 7,
28, and 56 in the spleen (Figure S5) and in MLNs
(Figure S6) are shown, respectively. The relative pro-
portion of CD4+ T cells and Treg cells increased in the
spleen on Day 56 in the lipo α‐GC group significantly.
The relative proportion of Tfh on Days 28 and 56 and
GCB on Day 56 in MLNs decreased in the lipo α‐GC
group significantly. We assumed that these data were
consistent with our hypothesis that lipo α‐GC may sup-
press the increase of Tfh and GCB and prevent the de-
velopment of chronic GVHD. In previous studies,
NKT‐cell‐depletion abolished the increase of Treg by
α‐GC and the suppression of acute GVHD. We assume
that NKT‐cell‐depletion could abolish the reduction of
Tfh and GCB and the suppression of chronic GVHD as
well, however it should be warranted by future studies.
The differential effect of lipo α‐GC on donor‐ and host‐
type iNKT cells is considered to be complicated. Previous
murine studies have suggested that stimulation of host‐type
iNKT cells by α‐GC play an important role in preventing
acute GVHD, but have not shown the kinetics of host‐ and
donor‐type iNKT after the injection of α‐GC. In this study,
we showed that lipo α‐GC treatment resulted in the reduc-
tion of host‐type iNKT and the increase of donor‐type iNKT
in spleen and lymph nodes (Figures 3 and S8). As described
above, we hypothesize that lipo α‐GC may promote the
FIGURE 6 CXCL13 concentration increases in the allo lipo α‐GC group and is correlated with the proportion of Tfh cells. (A)
Concentrations of CXCL13 in the plasma of syngeneic/vehicle (n= 2, one experiment), syngeneic/lipo α‐GC (n= 2, one experiment),
allogeneic/vehicle (n= 8, data combined from two independently performed experiments with four mice per experiments), and allogeneic/
lipo α‐GC (n= 8, data combined from two independently performed experiments with four mice per experiments) mice on Day 56. Data are
expressed as means ± SEM. (B–D) Each orange, green, red, and blue marker indicates the result from syngeneic/vehicle, syngeneic/lipo
α‐GC, allogeneic/vehicle, and allogeneic/lipo α‐GC, respectively. (B) Spearman's rank correlation between the percentage of Tfh cells in
MLNs and the plasma concentration of CXCL13 on Day 56 (r= .853, p< 10−6). (C) Spearman's rank correlation between the percentage of
Tfh cells in MLNs and the skin cGVHD score on Day 56 (r= .775, p< 10−5). (D) Spearman's rank correlation between the percentage of Tfh
cells in MLNs and the skin pathological score on Day 56 (r= .766, p< 10−5). cGVHD, chronic graft‐versus‐host disease; MLN, mesenteric
lymph nodes; Tfh, follicular helper T cell; α‐GC, α‐Galactosylceramide
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immigration of host‐type iNKT from the lymphoid organ to
the GVHD target organ and on the other hand promote the
increase of donor‐type iNKT in the lymphoid organs. Fur-
ther research will be needed to warrant this consideration.
In general, the inflammatory state can hamper Treg
homeostasis and reduced the population as shown in
autoimmune murine models including OVA‐induced
bronchial asthma and experimental autoimmune en-
cephalomyelitis and colitis.40–42 Furthermore, Treg de-
crease can result in the increase of Tfh through the
reduced function of CTLA‐4.23 As well as autoimmune
diseases, altered inflammatory environment after allo-
geneic HSCT hamper Treg homeostasis.43 Our data from
this study demonstrated that lipo α‐GC increased Treg
and decreased Tfh irrespective of the intensive in-
flammation early after HSCT. We consider it is an im-
portant finding for the clinical appliance of lipo α‐GC.
In conclusion, our data showed that multiple lipo
α‐GC administrations altered the early homeostasis of
both host‐ and donor‐derived iNKT cells and effectively
prevented sclerodermatous cGVHD through donor Treg
expansion, followed by the inhibition of Tfh and GCB
cells. This study demonstrated an important coordination
of T‐ and B‐cell immunity in the pathogenesis of cGVHD
and may provide a novel clinical strategy for the induc-
tion of immune tolerance after allogeneic HSCT.
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